Literature DB >> 23904758

Do we need another selective estrogen receptor modulator for the adjuvant treatment of breast cancer?

T Shenkier.   

Abstract

Entities:  

Year:  2013        PMID： 23904758      PMCID： PMC3728048          DOI： 10.3747/co.20.1466

Source DB:  PubMed          Journal:  Curr Oncol        ISSN： 1198-0052            Impact factor:   3.677


× No keyword cloud information.
  11 in total

1.  CYP2D6 genotype as a marker for benefit of adjuvant tamoxifen in postmenopausal women: lessons learned.

Authors:  Catherine M Kelly; Kathleen I Pritchard
Journal:  J Natl Cancer Inst       Date:  2012-03-06       Impact factor: 13.506

Review 2.  American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer.

Authors:  Harold J Burstein; Ann Alexis Prestrud; Jerome Seidenfeld; Holly Anderson; Thomas A Buchholz; Nancy E Davidson; Karen E Gelmon; Sharon H Giordano; Clifford A Hudis; Jennifer Malin; Eleftherios P Mamounas; Diana Rowden; Alexander J Solky; Maryfran R Sowers; Vered Stearns; Eric P Winer; Mark R Somerfield; Jennifer J Griggs
Journal:  J Clin Oncol       Date:  2010-07-12       Impact factor: 44.544

3.  Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters.

Authors:  Hiltrud Brauch; Werner Schroth; Matthew P Goetz; Thomas E Mürdter; Stefan Winter; James N Ingle; Matthias Schwab; Michel Eichelbaum
Journal:  J Clin Oncol       Date:  2012-10-22       Impact factor: 44.544

4.  Excellent outcomes with adjuvant toremifene or tamoxifen in early stage breast cancer.

Authors:  Jaime D Lewis; Anees B Chagpar; Elizabeth A Shaughnessy; Jacob Nurko; Kelly McMasters; Michael J Edwards
Journal:  Cancer       Date:  2010-05-15       Impact factor: 6.860

Review 5.  Toremifene versus tamoxifen for advanced breast cancer.

Authors:  Chen Mao; Zu-Yao Yang; Ben-Fu He; Shan Liu; Jun-Hua Zhou; Rong-Cheng Luo; Qing Chen; Jin Ling Tang
Journal:  Cochrane Database Syst Rev       Date:  2012-07-11

6.  Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93.

Authors:  Olivia Pagani; Shari Gelber; Karen Price; David Zahrieh; Richard Gelber; Edda Simoncini; Monica Castiglione-Gertsch; Alan S Coates; Aron Goldhirsch
Journal:  Ann Oncol       Date:  2004-12       Impact factor: 32.976

7.  Safety and efficacy results of a randomized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with node-positive breast cancer. Finnish Breast Cancer Group.

Authors:  K Holli; R Valavaara; G Blanco; V Kataja; P Hietanen; M Flander; E Pukkala; H Joensuu
Journal:  J Clin Oncol       Date:  2000-10-15       Impact factor: 44.544

8.  Role and pharmacologic significance of cytochrome P-450 2D6 in oxidative metabolism of toremifene and tamoxifen.

Authors:  Juhyun Kim; Christopher C Coss; Christina M Barrett; Michael L Mohler; Casey E Bohl; Chien-Ming Li; Yali He; Karen A Veverka; James T Dalton
Journal:  Int J Cancer       Date:  2012-09-14       Impact factor: 7.396

9.  Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.

Authors:  C Davies; J Godwin; R Gray; M Clarke; D Cutter; S Darby; P McGale; H C Pan; C Taylor; Y C Wang; M Dowsett; J Ingle; R Peto
Journal:  Lancet       Date:  2011-07-28       Impact factor: 79.321

10.  Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.

Authors:  Christina Davies; Hongchao Pan; Jon Godwin; Richard Gray; Rodrigo Arriagada; Vinod Raina; Mirta Abraham; Victor Hugo Medeiros Alencar; Atef Badran; Xavier Bonfill; Joan Bradbury; Michael Clarke; Rory Collins; Susan R Davis; Antonella Delmestri; John F Forbes; Peiman Haddad; Ming-Feng Hou; Moshe Inbar; Hussein Khaled; Joanna Kielanowska; Wing-Hong Kwan; Beela S Mathew; Indraneel Mittra; Bettina Müller; Antonio Nicolucci; Octavio Peralta; Fany Pernas; Lubos Petruzelka; Tadeusz Pienkowski; Ramachandran Radhika; Balakrishnan Rajan; Maryna T Rubach; Sera Tort; Gerard Urrútia; Miriam Valentini; Yaochen Wang; Richard Peto
Journal:  Lancet       Date:  2013-03-09       Impact factor: 79.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.